ECSP066274A - Saquinavir mesilato, forma de dosificacion oral - Google Patents

Saquinavir mesilato, forma de dosificacion oral

Info

Publication number
ECSP066274A
ECSP066274A EC2006006274A ECSP066274A ECSP066274A EC SP066274 A ECSP066274 A EC SP066274A EC 2006006274 A EC2006006274 A EC 2006006274A EC SP066274 A ECSP066274 A EC SP066274A EC SP066274 A ECSP066274 A EC SP066274A
Authority
EC
Ecuador
Prior art keywords
dosage form
saquinavir
mesilato
saquinavir mesylate
oral dosage
Prior art date
Application number
EC2006006274A
Other languages
English (en)
Inventor
Antonio A Albano
Martin Howard Infeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Ling Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066274(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP066274A publication Critical patent/ECSP066274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona una forma de dosificación farmacéutica sólida unitaria oral de saquinavir mesilato que contiene el saquinavir mesilato micronizado en una cantidad comprendida entre 250 mg y 800 mg, calculada como base libre, y un aglutinante farmacéuticamente aceptable, un desintegrante y un excipiente soluble en agua. Se proporciona una forma de dosificación sólida unitaria de saquinavir mesilato que contiene del 60% a 80% de saquinavir mesilato micronizado basado en la sal mesilato, del 4% al 8% de aglutinante soluble en agua, un desintegrante y un excipiente, en la que cada porcentaje se refiere al peso del núcleo.
EC2006006274A 2003-07-11 2006-01-09 Saquinavir mesilato, forma de dosificacion oral ECSP066274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48660003P 2003-07-11 2003-07-11
US56820404P 2004-05-05 2004-05-05

Publications (1)

Publication Number Publication Date
ECSP066274A true ECSP066274A (es) 2006-10-25

Family

ID=34068244

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006274A ECSP066274A (es) 2003-07-11 2006-01-09 Saquinavir mesilato, forma de dosificacion oral

Country Status (23)

Country Link
US (2) US20050009811A1 (es)
EP (1) EP1646369B1 (es)
JP (2) JP4608488B2 (es)
KR (2) KR100767271B1 (es)
AU (1) AU2004255436B2 (es)
BR (1) BRPI0412523A (es)
CA (1) CA2531486C (es)
CO (1) CO5640069A2 (es)
CR (1) CR8172A (es)
EA (1) EA015349B1 (es)
EC (1) ECSP066274A (es)
IL (1) IL172890A (es)
MA (1) MA27904A1 (es)
MX (1) MXPA06000363A (es)
MY (1) MY140413A (es)
NO (1) NO20060313L (es)
NZ (1) NZ544585A (es)
PA (1) PA8606001A1 (es)
PE (1) PE20050247A1 (es)
RS (1) RS20060009A (es)
TN (1) TNSN06003A1 (es)
TW (1) TWI356711B (es)
WO (1) WO2005004836A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
NZ544585A (en) * 2003-07-11 2008-04-30 Hoffmann La Roche Saquinavir mesylate oral dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
EP3870167A4 (en) * 2018-10-23 2022-07-27 Eastern Virginia Medical School PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR MANUFACTURE OF SOLID DOSAGE FORMS ON REQUEST

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0616841B1 (en) * 1992-10-09 1998-12-23 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Production method for fine granulate
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
MXPA01006108A (es) * 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
NZ544585A (en) * 2003-07-11 2008-04-30 Hoffmann La Roche Saquinavir mesylate oral dosage form

Also Published As

Publication number Publication date
CR8172A (es) 2006-10-04
PA8606001A1 (es) 2005-03-03
JP2009501694A (ja) 2009-01-22
KR100767271B1 (ko) 2007-10-17
CA2531486A1 (en) 2005-01-20
US20090054481A1 (en) 2009-02-26
NO20060313L (no) 2006-02-09
CO5640069A2 (es) 2006-05-31
MY140413A (en) 2009-12-31
BRPI0412523A (pt) 2006-09-19
AU2004255436B2 (en) 2006-11-30
NZ544585A (en) 2008-04-30
MXPA06000363A (es) 2006-03-28
TW200505504A (en) 2005-02-16
TNSN06003A1 (en) 2007-10-03
MA27904A1 (fr) 2006-05-02
TWI356711B (en) 2012-01-21
IL172890A (en) 2013-11-28
WO2005004836A3 (en) 2005-05-12
US20050009811A1 (en) 2005-01-13
EA015349B1 (ru) 2011-06-30
KR20060056320A (ko) 2006-05-24
WO2005004836A2 (en) 2005-01-20
EP1646369A2 (en) 2006-04-19
HK1089959A1 (en) 2006-12-15
EP1646369B1 (en) 2019-04-10
IL172890A0 (en) 2006-06-11
CA2531486C (en) 2012-10-02
RS20060009A (sr) 2008-06-05
JP4608488B2 (ja) 2011-01-12
AU2004255436A1 (en) 2005-01-20
PE20050247A1 (es) 2005-04-13
KR20070087194A (ko) 2007-08-27
EA200600156A1 (ru) 2006-08-25
JP2010280707A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
AR019935A1 (es) Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
AR036312A1 (es) Composicion farmaceutica
BR0114100A (pt) Formulações de liberação controlada para administração oral
ECSP066274A (es) Saquinavir mesilato, forma de dosificacion oral
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
MY144781A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
UY28457A1 (es) Nueva composición
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
AR045897A1 (es) Saquinavir mesilato, forma de dosificacion oral
DOP2004000950A (es) Saquinavir mesilato, forma de dosificacion oral